23 okt: Få VIP-billet til Invest 2007 - kvit og frit
24 okt: Fabricius og Kastholms møbelklassikere
24-10-2006 11:39:00

Hugin Ad hoc announcement according to § 15 WpHG: Misc. business figure: STRATEC Biomedical Systems AG: STRATEC clearly exceeds earnings for overall previous year after only nine months

Birkenfeld, October 24, 2006

The Board of Management of STRATEC Biomedical Systems AG, which is

listed in the Prime Standard and Gate-M indices, hereby announces the

preliminary, unaudited consolidated figures based on IFRS

(International Financial Reporting Standards) of the STRATEC Group

for the first nine months of the 2006 financial year pursuant to

Section 15 of the German Securities Trading Act (WpHG).

+-------------------------------------------------------------------+

| Key Figures (EUR | 01.01.- | 01.01.- | Change |

| 000s) | 09.30.2006 | 09.30.2005 | |

|---------------------+-----------------+-----------------+---------|

| Sales | 51,933 | 33,945 | + 53.0% |

|---------------------+-----------------+-----------------+---------|

| Gross performance | 51,887 | 35,582 | + 45.8% |

|---------------------+-----------------+-----------------+---------|

| EBITDA | 8,295 | 5,315 | + 56.1% |

|---------------------+-----------------+-----------------+---------|

| EBIT | 7,199 | 4,587 | + 56.9% |

|---------------------+-----------------+-----------------+---------|

| EBT | 7,097 | 4,409 | + 61.0% |

|---------------------+-----------------+-----------------+---------|

| Consolidated net | 5,304 | 2,895 | + 83.2% |

| income | | | |

|---------------------+-----------------+-----------------+---------|

| Earnings per share | 0.48 | 0.29 | + 65.5% |

| (EUR) | | | |

+-------------------------------------------------------------------+

The STRATEC Group had a total of 215 employees as of

September 30, 2006 (previous year: 189).

Information and disclosures concerning this ad-hoc announcement:

Irrespective of possible new levels of sales and earnings correlating

with the market launch of new analyzer system families, the company

assumes that the seasonal fluctuations witnessed in sales and

earnings in the past will be increasingly countered by logistical

measures involving procurement and production.

In the past 2005 financial year, the STRATEC Group had an average of

191 employees and generated sales of Euro 47.3 million, earnings

before tax (EBT) of Euro 6.9 million and consolidated income of Euro

4.4 million, with earnings per share of Euro 0.43 (earnings for

overall previous year).

The extensive interim report will be available on our internet page

as a download from around 3 p.m. on November 8, 2006.

Based on current budgeting, the growth forecast for the company will

be reflected in particular from the second and third quarter of the

2007 financial year onwards.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)

designs and manufactures fully automated systems for its partners in

the fields of clinical diagnostics and biotechnology. These partners

market such systems, in general together with their own reagents, to

laboratories and research institutes around the world. The company

develops its products on the basis of its own patented technologies.

Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded

in the Prime Standard segment of the Frankfurt Stock Exchange, in the

Gate-M trading segment of the Stuttgart Stock Exchange and on other

exchanges.

The STRATEC Group comprises the listed holding company "STRATEC

Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",

"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG

André Loy, Investor Relations

Gewerbestrasse 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

E-Mail: ir@stratec-biomedical.de

--- End of Ad-hoc Message ---

WKN: 728900; ISIN: DE0007289001;

Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in

Börse Stuttgart,

Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse

München,

Freiverkehr in Börse Düsseldorf;

Copyright © Hugin ASA . All rights reserved.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 okt
EI
Til direktionen.     Se så at få fyret den uduelige person, som I har ansat som moderator. Vedkommen..
43
18 okt
NOVO-B
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee votes 16 - 0 in favor of approval fo..
21
14 okt
PNDORA
Har efterhånden læst mange indlæg om Pandora her på Euroinvestor. De fleste indlæg er enten beregne..
21
18 okt
EI
Og til Moderator:     Du UNDERSTÅR dig i at fjerne dette indlæg uden at have forelagt det direktione..
17
13 okt
PNDORA
Det ligger klart for enhver at med vaekst rater over 10 procent om aaret, som vedholdende vil blive ..
16
16 okt
OMXC25
Jeg har fuldstændig mistet enhver form for respekt for EU.   EU er i den grad blevet til en taberfor..
14
18 okt
EI
Måske meget ville være vundet hvis vi alle erkendte, at vi alle sammen er her på siden for at udveks..
13
18 okt
PNDORA
Markedsværdi = DKK 64 milliarder   Pandora ejer 2,30 % af aktierne (som vi må antage ikke kommer i o..
12
16 okt
VWS
Kommentarer, hvorfor anvender du nu en periode på 13 måneder, når du ser tilbage for at sammenligne ..
12
19 okt
PNDORA
Du burde have 6 måneders karantæne
11

Nye digitale betalingsløsninger bryder frem

25-09-2017 08:45:00
Sponsoreret indhold:Af Jens Damgaard, Country Manager, Visa DenmarkEfter 20 år, hvor danskerne har taget imod ganske mange nye løsninger indenfor elektroniske/digitale betalinger, går udviklingen nu endnu hurtigere, og det gør Danmark til et af de mest avancerede betalingsmarkeder i Europa. Avanceret, fordi danskerne er parat til at bruge næsten enhver tænkelig mobil enhed til at betale med.Buti..

Novo: Fiasp godkendt i USA

29-09-2017 16:20:48
De amerikanske sundhedsmyndigheder, FDA, har godkendt Fiasp (hurtigtvirkende insulin aspart), en ny hurtigtvirkende måltidsinsulin, til behandling af voksne med diabetes.Det oplyser Novo Nordisk.FDA's beslutning kommer, efter at kliniske studier har dokumenteret, at Fiasp giver fordele for mennesker, der har behov for en forbedret generel blodsukkerregulering.- Vi er meget glade for, at Fiasp nu o..

Atlantic Petroleum: Direktør fratræder 1. december

29-09-2017 14:02:37
Topchefen for Atlantic Petroleum, der er noteret i Norge og København, direktør Ben Arabo, har opsagt sit job for at tiltræde et andet job på Færøerne.Det oplyser selskabet.Han vil dog blive hos Atlantic Petroleum til 1. december./ritzau/FINANSClaus Mikkelsen +45 33 30 03 35 Ritzau Finans, E-mail: finans@ritzau.dk , www.ritzaufinans.dk

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas sætter gang i første store sol-, vind- og batteriprojekt
2
Novo/Sydbank: Ser aktien stige 3-4 pct. efter positiv anbefaling
3
Aktier/middag: Kun Pandora og Novo undgår sur markedsstemning
4
Novo/ABM: Ventet afgørelse giver den afdæmpede kursreaktion
5
Pandora/Carnegie: Svær september var et lavpunkt - god start på Q4

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. oktober 2017 03:33:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171019.2 - EUROWEB1 - 2017-10-20 03:33:06 - 2017-10-20 03:33:06 - 1 - Website: OKAY